Abstract
Thousands of genetic variants in protein-coding genes have been linked to disease. However, the functional impact of most variants is unknown as they occur within intrinsically disordered protein regions that have poorly defined functions1–3. Intrinsically disordered regions can mediate phase separation and the formation of biomolecular condensates, such as the nucleolus4,5. This suggests that mutations in disordered proteins may alter condensate properties and function6–8. Here we show that a subset of disease-associated variants in disordered regions alter phase separation, cause mispartitioning into the nucleolus and disrupt nucleolar function. We discover de novo frameshift variants in HMGB1 that cause brachyphalangy, polydactyly and tibial aplasia syndrome, a rare complex malformation syndrome. The frameshifts replace the intrinsically disordered acidic tail of HMGB1 with an arginine-rich basic tail. The mutant tail alters HMGB1 phase separation, enhances its partitioning into the nucleolus and causes nucleolar dysfunction. We built a catalogue of more than 200,000 variants in disordered carboxy-terminal tails and identified more than 600 frameshifts that create arginine-rich basic tails in transcription factors and other proteins. For 12 out of the 13 disease-associated variants tested, the mutation enhanced partitioning into the nucleolus, and several variants altered rRNA biogenesis. These data identify the cause of a rare complex syndrome and suggest that a large number of genetic variants may dysregulate nucleoli and other biomolecular condensates in humans.
| Original language | English |
|---|---|
| Journal | Nature |
| Volume | 614 |
| Issue number | 7948 |
| Pages (from-to) | 564-571 |
| Number of pages | 8 |
| ISSN | 0028-0836 |
| DOIs | |
| Publication status | Published - 16.02.2023 |
Funding
We thank the patients and their families for participating in this study; V. Suckow, G. Hildebrand, V. Johnston and Y. Zhang for technical assistance; T. Aktas (MPI-MG) for comments on the manuscript; A. Papantonis (GAU, Göttingen) for advice on HMGB1 immunofluorescence; and U. Marchfelder and E. Weiß from the Flow Cytometry Facility of the MPI-MG for their assistance with cell sorting; D. Meierhofer and B. Lukaszewska-McGreal for performing mass spectrometry; and J. Naderi for mCherry constructs and human iPS cells. M.A.M. is a participant in the Digital Clinician Scientist Program and H.L.S. in the Junior Clinician Scientist Program founded by the late D. Dragun and funded by the Berlin Institute of Health and the Charité–Universitätsmedizin Berlin. This work was partially funded by the Max Planck Society. Work in the Hnisz Lab is supported by the Deutsche Forschungsgemeinschaft (DFG) Priority Program Grants HN 4/1-1 and HN 4/3-1 and a Worldwide Cancer Research grant (20-0232). M.S. is supported by grants from the DFG (SP1532/3-2, SP1532/4-1 and SP1532/5-1) and the Deutsches Zentrum für Luft- und Raumfahrt (DLR 01GM1925). S.M. was funded by grant MU 880/16-1 from the DFG. H. Niskanen is supported by fellowships from the Orion Research Foundation and the Instrumentarium Science Foundation. C.G.-C. acknowledges a graduate fellowship from MINECO (PRE2018-084684) and X.S. acknowledges funding from AGAUR (2017 SGR 324), MINECO (PID2019-110198RB-I00) and the European Research Council (CONCERT, contract number 648201). IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain).
Research Areas and Centers
- Research Area: Medical Genetics
- Centers: Center for Rare Diseases (ZSE)
DFG Research Classification Scheme
- 2.22-03 Human Genetics